NOVARTIS CAPI015A2201J
Back to Drug Development Trials
![]()
Drug Development Trials
About the trial
As Phase 2/3 randomized, double-blinded, placebo-controlled, two-cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer’s disease.
